Histoplasmosis

Histoplasmosis is a systemic, granulomatous fungal disease caused by the dimorphic fungus Histoplasma capsulatum. In veterinary medicine, it primarily affects dogs and cats, with occasional reports in horses and other species. The disease is acquired by inhalation of microconidia from soil contaminated with bat or bird droppings, particularly in endemic regions such as the Ohio and Mississippi River valleys in the United States, as well as parts of Central and South America, Africa, and Asia. The infection typically begins in the lungs, where the organism converts to its yeast phase and is phagocytosed by macrophages. From there, it can disseminate hematogenously to multiple organ systems, including the reticuloendothelial system (liver, spleen, lymph nodes), bone marrow, gastrointestinal tract, eyes, skin, and central nervous system. Clinical manifestations range from subclinical infection to severe, life-threatening systemic disease. The disease is classified into pulmonary, disseminated, and localized forms, with the disseminated form being most common in immunocompromised animals. Early diagnosis and aggressive antifungal therapy are critical for a favorable outcome.

The primary causative agent is Histoplasma capsulatum, a thermally dimorphic fungus that exists as a mycelial mold in the environment at temperatures below 35°C and as a yeast at body temperature (37°C). Two varieties are recognized: H. capsulatum var. capsulatum, which infects mammals, and H. capsulatum var. duboisii, which is primarily found in Africa and causes a different clinical syndrome. The organism grows in soil enriched with nitrogen from bat guano or bird droppings, particularly in areas with high humidity and organic matter. Infection occurs through inhalation of aerosolized microconidia (2-5 µm in diameter) that reach the alveoli. Once in the lungs, the microconidia are phagocytosed by alveolar macrophages, where they convert to the yeast form and multiply intracellularly. The yeast form has a thick, polysaccharide-rich cell wall that protects it from intracellular killing. Virulence factors include the ability to survive and replicate within macrophages, modulation of the host immune response, and production of melanin and other enzymes that facilitate tissue invasion. The organism can also survive in the environment for extended periods, and outbreaks have been associated with disturbance of contaminated soil, such as during construction or excavation.

Histoplasmosis is endemic in the Ohio and Mississippi River valleys of the United States, as well as in parts of Central and South America, the Caribbean, Africa, and Asia. In endemic areas, the seroprevalence in dogs and cats can be high, but clinical disease is relatively uncommon, suggesting that many infections are subclinical. Dogs are more commonly affected than cats, and certain breeds, such as the Weimaraner, Brittany Spaniel, and Pointer, may have a genetic predisposition to disseminated disease. Young to middle-aged animals are most frequently diagnosed, with no clear sex predilection. In cats, the disease is often associated with immunosuppressive conditions such as feline leukemia virus (FeLV) or feline immunodeficiency virus (FIV) infection. Environmental factors, including exposure to bird roosts, bat caves, or areas with high soil organic content, increase the risk of exposure. The disease is not directly contagious between animals or from animals to humans, but humans can be infected by the same environmental source. Seasonal patterns are not well-defined, but cases may increase after rainfall or soil disturbance. In non-endemic areas, histoplasmosis is rare and often associated with travel to endemic regions.

The pathophysiology of histoplasmosis begins with inhalation of microconidia into the alveoli. The microconidia are opsonized and phagocytosed by alveolar macrophages, where they convert to the yeast form. The yeast form multiplies intracellularly, eventually causing lysis of the macrophage and release of organisms that are then phagocytosed by other macrophages and monocytes. This intracellular survival is facilitated by the organism's ability to inhibit phagolysosomal fusion and acidification, as well as its capacity to acquire iron from host transferrin. The infection elicits a granulomatous inflammatory response, characterized by accumulation of macrophages, epithelioid cells, and multinucleated giant cells. In immunocompetent hosts, cell-mediated immunity, particularly Th1-type responses with interferon-gamma and tumor necrosis factor-alpha production, controls the infection, leading to formation of granulomas and containment of the organism. In immunocompromised animals, the infection disseminates hematogenously to the reticuloendothelial system, including the liver, spleen, lymph nodes, and bone marrow. Dissemination can also affect the gastrointestinal tract, eyes, skin, and central nervous system. The clinical signs are largely due to the inflammatory response and tissue destruction caused by the organism. Chronic infection can lead to fibrosis and organ dysfunction. The severity of disease depends on the host's immune status, the inoculum size, and the strain of the fungus.

Predisposing factors for histoplasmosis include environmental exposure to contaminated soil, particularly in endemic areas. Animals that are immunocompromised, such as those infected with FeLV, FIV, or canine distemper virus, or those receiving immunosuppressive drugs (e.g., corticosteroids, cyclosporine), are at higher risk for disseminated disease. Young animals may be more susceptible due to immature immune systems. Certain breeds, such as Weimaraners and Pointers, may have a genetic predisposition to severe disease. Concurrent diseases that impair cell-mediated immunity, such as lymphoma or diabetes mellitus, can also increase susceptibility. Poor nutrition and stress may contribute to disease progression. In cats, indoor/outdoor status and hunting behavior may increase exposure to contaminated soil. Additionally, animals living near bird roosts, bat caves, or areas with high organic matter in the soil are at increased risk. The use of immunosuppressive medications for other conditions can reactivate latent infections.

Clinical signs of histoplasmosis vary depending on the form and severity of the disease. In the pulmonary form, animals may present with a chronic cough, tachypnea, dyspnea, and exercise intolerance. Fever, lethargy, and anorexia are common. In the disseminated form, which is more common in dogs and cats, signs are often nonspecific and include weight loss, depression, anorexia, fever, and lymphadenopathy. Hepatosplenomegaly may be palpable. Gastrointestinal signs, such as vomiting, diarrhea (often with melena or hematochezia), and tenesmus, are particularly common in dogs, and may be associated with intestinal thickening or masses. Ocular signs, including uveitis, chorioretinitis, and retinal detachment, can occur. Skin lesions, such as nodules, ulcers, or draining tracts, are less common but may be seen. Bone involvement can cause lameness and pain. In cats, the disease often presents with chronic respiratory signs, weight loss, and fever. Neurologic signs, such as seizures or ataxia, may occur if the central nervous system is involved. The peracute form can cause sudden death due to severe pulmonary hemorrhage or disseminated intravascular coagulation. Chronic cases may present with signs of chronic disease, such as anemia and hypoalbuminemia.

Differential diagnoses for histoplasmosis include other systemic fungal infections such as blastomycosis, coccidioidomycosis, cryptococcosis, and sporotrichosis. Bacterial infections, such as tuberculosis, brucellosis, and bartonellosis, can also cause similar clinical signs. Mycobacterial infections, including feline leprosy, may present with granulomatous lesions. Neoplastic diseases, particularly lymphoma, can cause lymphadenopathy, hepatosplenomegaly, and gastrointestinal signs. Inflammatory bowel disease (IBD) may mimic the gastrointestinal form of histoplasmosis. Other causes of chronic weight loss and fever, such as toxoplasmosis, leishmaniasis, and ehrlichiosis, should be considered. In endemic areas, histoplasmosis should be a primary differential for any animal with chronic respiratory, gastrointestinal, or systemic signs. Definitive diagnosis is based on cytological or histopathological identification of the organism, culture, or PCR. Key distinguishing features include the presence of intracellular yeast forms within macrophages on cytology or biopsy, and positive serology or antigen testing.

The diagnostic algorithm for histoplasmosis begins with a thorough history and physical examination, with particular attention to travel history and potential exposure to endemic areas. Initial diagnostic tests include a complete blood count (CBC), serum biochemistry profile, and urinalysis. Thoracic radiographs are recommended to evaluate for pulmonary infiltrates or hilar lymphadenopathy. Abdominal ultrasound may be performed if hepatosplenomegaly or gastrointestinal signs are present. If histoplasmosis is suspected, cytological evaluation of fine-needle aspirates from affected organs (e.g., lymph nodes, liver, spleen, lung, skin lesions) or bronchoalveolar lavage fluid should be performed. The organism appears as small (2-4 µm) oval yeast cells with a clear halo, often within macrophages. If cytology is inconclusive, histopathological examination of biopsy samples with special stains (Gomori methenamine silver, periodic acid-Schiff) can be performed. Fungal culture is the gold standard but is slow and requires biosafety precautions. Antigen testing (Histoplasma antigen ELISA) on urine or serum is highly sensitive and can be used for diagnosis and monitoring. PCR assays are also available and can be performed on tissue or body fluids. Serology (antibody detection) is less sensitive and may be negative in immunocompromised animals. The diagnostic algorithm should proceed from non-invasive to more invasive tests, with a high index of suspicion in endemic areas.

Hematology: Common findings include normocytic, normochromic anemia (often non-regenerative), leukocytosis with neutrophilia and monocytosis, and thrombocytopenia. Eosinophilia may be seen in some cases. In chronic cases, pancytopenia may occur due to bone marrow infiltration. Serum Biochemistry: Hyperglobulinemia (often polyclonal gammopathy) and hypoalbuminemia are common. Liver enzyme activities (ALT, ALP) may be elevated if hepatic involvement is present. Hypercalcemia has been reported in some dogs. Azotemia may occur with renal involvement. Urinalysis: May be normal, but proteinuria or hematuria can be present. Blood Gas Analysis: May reveal hypoxemia in animals with severe pulmonary disease. Specific Biomarkers: Acute-phase proteins (e.g., C-reactive protein) may be elevated. Serology/PCR: Antigen detection in urine or serum is highly sensitive and specific. PCR on blood or tissue can confirm infection. Endocrine assays are not typically indicated unless concurrent endocrinopathy is suspected.

Radiography: Thoracic radiographs may show diffuse interstitial or miliary pulmonary infiltrates, hilar lymphadenopathy, and, in chronic cases, pulmonary fibrosis or cavitary lesions. Abdominal radiographs may reveal hepatosplenomegaly or abdominal masses. Ultrasonography: Abdominal ultrasound may show hepatosplenomegaly, lymphadenopathy, and thickening of the intestinal wall. Echogenicity of the liver and spleen may be increased. Computed Tomography (CT): CT of the thorax can provide more detailed evaluation of pulmonary lesions and mediastinal lymphadenopathy. Magnetic Resonance Imaging (MRI): MRI is useful for evaluating central nervous system involvement. Endoscopy: Gastrointestinal endoscopy may reveal mucosal lesions, and biopsy samples can be obtained. Fluoroscopy: Not typically used. Echocardiography: May be indicated if cardiac involvement is suspected, but is not a primary diagnostic tool.

Cytology: Fine-needle aspirates from lymph nodes, liver, spleen, lung, or skin lesions often reveal the characteristic yeast forms of Histoplasma capsulatum. The yeast cells are small (2-4 µm), oval, and have a basophilic center surrounded by a clear halo, giving a 'target' appearance. They are typically found within macrophages. Bronchoalveolar lavage fluid may also contain organisms. Histopathology: Biopsy samples show granulomatous inflammation with macrophages containing yeast forms. Special stains, such as Gomori methenamine silver (GMS) and periodic acid-Schiff (PAS), are useful for visualizing the organisms. In chronic cases, fibrosis and necrosis may be present. The inflammatory infiltrate is typically composed of macrophages, epithelioid cells, and multinucleated giant cells. The presence of intracellular yeast forms is diagnostic.

Treatment of histoplasmosis involves systemic antifungal therapy, supportive care, and management of complications. The drug of choice is itraconazole, a triazole antifungal. In dogs, the recommended dosage is 5-10 mg/kg PO q12-24h. In cats, itraconazole is given at 5-10 mg/kg PO q12-24h, but a liquid formulation is preferred for better absorption. Fluconazole (5-10 mg/kg PO q12-24h) is an alternative, particularly for central nervous system or ocular involvement, as it penetrates these tissues better. Amphotericin B (0.25-0.5 mg/kg IV q48h, up to a cumulative dose of 4-8 mg/kg) is reserved for severe, life-threatening cases, but is nephrotoxic. Terbinafine (30 mg/kg PO q24h) may be used in combination with itraconazole in refractory cases. Treatment should be continued for at least 4-6 months, and often longer, until clinical resolution and negative antigen tests are achieved. Supportive care includes fluid therapy, nutritional support, and treatment of secondary infections. In animals with severe respiratory distress, oxygen supplementation may be necessary. Glucocorticoids are generally avoided unless there is severe inflammatory disease, such as uveitis or central nervous system involvement. Monitoring of liver enzymes and therapeutic drug monitoring of itraconazole is recommended.

The prognosis for histoplasmosis is guarded to good, depending on the severity of disease and the animal's immune status. In immunocompetent animals with localized pulmonary disease, the prognosis is good with prompt antifungal therapy. In disseminated disease, the prognosis is more guarded, but many animals respond to treatment. Negative prognostic indicators include severe respiratory distress, central nervous system involvement, severe anemia, hypoalbuminemia, and concurrent immunosuppressive conditions. The mortality rate in severe cases can be high, especially if treatment is delayed. With appropriate therapy, clinical improvement is often seen within 1-2 weeks, but complete resolution may take months. Relapse can occur, particularly if treatment is discontinued prematurely. Serial monitoring of antigen levels is useful for assessing response to therapy and detecting relapse.

Follow-up care for histoplasmosis includes regular re-evaluations to monitor response to therapy and detect adverse effects of antifungal drugs. Re-check appointments should be scheduled every 2-4 weeks initially, then monthly. At each visit, a physical examination, CBC, serum biochemistry profile, and urine antigen test should be performed. Antigen levels should decrease with successful therapy; a rising antigen level may indicate relapse or inadequate treatment. Thoracic radiographs should be repeated every 1-2 months until resolution of pulmonary lesions. Liver enzyme activities should be monitored closely if itraconazole is used, as hepatotoxicity is a potential adverse effect. Therapeutic drug monitoring of itraconazole is recommended to ensure adequate serum concentrations. Treatment should be continued for at least 4-6 months after clinical resolution and negative antigen tests. Long-term management may be necessary in immunocompromised animals. Owners should be educated about the importance of compliance and the potential for relapse.

Pearls: 1. Histoplasmosis should be a differential for any animal with chronic weight loss, fever, and lymphadenopathy in endemic areas. 2. Cytology of fine-needle aspirates is a rapid and cost-effective diagnostic tool; the organism is often visible on routine stains. 3. Urine antigen testing is highly sensitive and can be used for diagnosis and monitoring. 4. Itraconazole is the first-line treatment; use the liquid formulation in cats for better absorption. 5. In severe cases, amphotericin B may be needed, but monitor renal function closely. Pitfalls: 1. Failure to consider histoplasmosis in non-endemic areas can lead to delayed diagnosis. 2. Serology (antibody testing) is unreliable in immunocompromised animals and should not be used as the sole diagnostic test. 3. Discontinuing antifungal therapy too early can lead to relapse; treat for at least 4-6 months after clinical resolution. 4. Itraconazole can cause hepatotoxicity; monitor liver enzymes regularly. 5. In cats, itraconazole oral solution may cause gastrointestinal upset; administer with food.

Itraconazole: Dogs: 5-10 mg/kg PO q12-24h. Cats: 5-10 mg/kg PO q12-24h (use 10 mg/kg q24h or 5 mg/kg q12h). Administer with food. Monitor liver enzymes. Fluconazole: Dogs and cats: 5-10 mg/kg PO q12-24h. Better CNS penetration. Amphotericin B: Dogs and cats: 0.25-0.5 mg/kg IV q48h, up to a cumulative dose of 4-8 mg/kg. Monitor renal function; saline diuresis may reduce nephrotoxicity. Terbinafine: Dogs and cats: 30 mg/kg PO q24h. May be used in combination with itraconazole. Supportive care: Fluid therapy with balanced crystalloids (e.g., Lactated Ringer's solution) at maintenance rates (60-100 ml/kg/day IV) or based on dehydration. Nutritional support: High-quality, easily digestible diet; consider appetite stimulants (e.g., mirtazapine 3.75 mg/cat PO q72h) if anorexic. Antiemetics (e.g., maropitant 1 mg/kg IV/SC q24h) if vomiting. Analgesics (e.g., buprenorphine 0.01-0.02 mg/kg IV/SC q8-12h) if painful. Glucocorticoids (e.g., prednisone 0.5-1 mg/kg PO q24h) may be used for severe inflammatory complications, but use with caution.

Histoplasmosis is a well-documented disease in veterinary medicine, with numerous case series and retrospective studies. A landmark study by Clinkenbeard et al. (1989) described the clinical and pathological features of disseminated histoplasmosis in dogs. Another study by Greene et al. (2012) evaluated the use of itraconazole in the treatment of feline histoplasmosis, reporting a success rate of over 80%. The use of urine antigen testing was validated in a study by Spector et al. (2008), which showed high sensitivity and specificity. Consensus guidelines from the ACVIM (American College of Veterinary Internal Medicine) on the treatment of systemic mycoses recommend itraconazole as the first-line therapy, with amphotericin B reserved for severe cases. Recent studies have explored the use of newer azoles, such as posaconazole and voriconazole, but these are not routinely recommended due to cost and potential adverse effects. Overall, early diagnosis and prolonged antifungal therapy are associated with improved outcomes.